Norman Gaylis

2.0k citations

35 papers · 1.2k indexed · 1 hit paper · h-index 16

Co-authors: Jonathan Kay Josef S Smolen Elizabeth C. Hsia Frederick T. Murphy Eric L. Matteson Mittie K. Doyle Robert Landewé Yiying Zhou
Topics: Rheumatoid Arthritis Research and Therapies (22 papers)Systemic Lupus Erythematosus Research (12 papers)Autoimmune and Inflammatory Disorders Research (10 papers)
Cited by: Rheumatology Hematology Genetics
Journals: The Lancet Clinical Infectious Diseases Annals of the Rheumatic Diseases
Partner nations: United States Germany Netherlands

In The Last Decade

Norman Gaylis

34 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers

Countries citing papers authored by Norman Gaylis

Since Specialization

Citations

This map shows the geographic impact of Norman Gaylis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman Gaylis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman Gaylis more than expected).

Fields of papers citing papers by Norman Gaylis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norman Gaylis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman Gaylis. The network helps show where Norman Gaylis may publish in the future.

Co-authorship network of co-authors of Norman Gaylis

This figure shows the co-authorship network connecting the top 25 collaborators of Norman Gaylis. A scholar is included among the top collaborators of Norman Gaylis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norman Gaylis. Norman Gaylis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study 2025 ·Rheumatology and Therapy ·Norman Gaylis,David Sikes,Alan Kivitz,Diane Horowitz,(unknown),Yaakov A. Levine,David Chernoff	0
2	‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar 2024 ·Advances in Therapy ·Norman Gaylis,(unknown),(unknown),Oliver von Richter,Paul S. Yamauchi	2
3	The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID 2022 ·Frontiers in Nutrition ·Norman Gaylis,(unknown),(unknown),(unknown),Yankel Gabet	7
4	Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS) 2021 ·BioDrugs ·Andrew Blauvelt,Craig L. Leonardi,Norman Gaylis,(unknown),Alison Balfour,(unknown),(unknown),(unknown),(unknown),Piotr Wiland	11
5	Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study 2020 ·The Lancet Rheumatology ·Mark C. Genovese,Norman Gaylis,David Sikes,Alan Kivitz,Diane Horowitz,Charles Peterfy,Emmett V. Glass,Yaakov A. Levine,David Chernoff	81
6	Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study 2020 ·BioDrugs ·Piotr Wiland,Sławomir Jeka,Eva Dokoupilová,(unknown),(unknown),(unknown),Raúl Veiga Cabello,(unknown),(unknown),(unknown),(unknown),Norman Gaylis	31
7	Patient Perspectives on Intravenous Biologics for Rheumatologic Disease 2018 ·Arthritis Care & Research ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Raphael J. DeHoratius,Norman Gaylis	7
8	Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy 2017 ·Patient Preference and Adherence ·Norman Gaylis,(unknown),Shawn C. Black,Kezhen L. Tang,Raphael J. DeHoratius,(unknown),Dennis Parenti	3
9	Proceedings from the 7th Annual International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) conference 2015 ·Seminars in Arthritis and Rheumatism ·O. Troum,(unknown),Wolfgang Schmidt,Mikkel Østergaard,Maria Antonietta D’Agostino,Norman Gaylis,William J. Arnold,Ami Ben‐Artzi,Veena K. Ranganath,(unknown),Charles Peterfy	1
10	Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study 2014 ·BMC Musculoskeletal Disorders ·(unknown),(unknown),Maria Greenwald,Joel M. Kremer,Norman Gaylis,William F. C. Rigby,Steve Zlotnick,Carol Chung,Birgit Jaber,William Reiss	29
11	Proceedings from the 5th Annual International Society for Musculoskeletal Imaging in Rheumatology Annual Conference 2013 ·Seminars in Arthritis and Rheumatism ·Philip G. Conaghan,Mikkel Østergaard,Maria Antonietta D’Agostino,Norman Gaylis,W. David Arnold,Ewa Olech,Alvin F. Wells,Charles Peterfy,(unknown),O. Troum	1
12	Long-Term Follow-Up of an HIV-Infected Patient With Reactive Arthritis Treated With Infliximab 2012 ·JCR Journal of Clinical Rheumatology ·Norman Gaylis	17
13	Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI 2012 ·Arthritis Research & Therapy ·Charles Peterfy,Julie C. DiCarlo,Ewa Olech,(unknown),Annarita Gabriele,Norman Gaylis	34
14	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 2012 ·Annals of the Rheumatic Diseases ·Josef S Smolen,Jonathan Kay,Robert Landewé,Eric L. Matteson,Norman Gaylis,J. Wollenhaupt,Frederick T. Murphy,Yiying Zhou,Elizabeth C. Hsia,Mittie K. Doyle	49
15	Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience 2011 ·The Journal of Rheumatology ·Charles Peterfy,P.J. Countryman,Annarita Gabriele,Tim Shaw,Andrew M. Anisfeld,Wayne Tsuji,Ewa Olech,Norman Gaylis,Philip G. Conaghan,Vibeke Strand,Julie C. DiCarlo	17
16	Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis 2011 ·Lara D. Veeken ·(unknown),(unknown),Andrea Rubbert‐Roth,Jeffrey R. Curtis,Ulf Müller‐Ladner,Norman Gaylis,S. Williams,(unknown),Helen E.J. Tyrrell	43
17	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialbreakdown → 2009 ·The Lancet ·Josef S Smolen,Jonathan Kay,Mittie K. Doyle,Robert Landewé,Eric L. Matteson,J. Wollenhaupt,Norman Gaylis,Frederick T. Murphy,Jeffrey Neal,Yiying Zhou,Sudha Visvanathan,Elizabeth C. Hsia,Mahboob U. Rahman	423
18	In-office magnetic resonance imaging to monitor responses to therapy in rheumatoid arthritis 2009 ·Rheumatology International ·Norman Gaylis,(unknown)	3
19	Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis 2007 ·Modern Rheumatology ·Norman Gaylis,(unknown),(unknown)	13
20	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study 2007 ·Annals of the Rheumatic Diseases ·D E Furst,Norman Gaylis,(unknown),Ewa Olech,David E. Yocum,J. Ritter,M H Weisman,(unknown),John V. Crues,Dinesh Khanna,Gisela Eckel,Newman Yeilding,(unknown),Sudha Visvanathan,(unknown),(unknown),Liziamma George,(unknown),(unknown),O. Troum	88

About Norman Gaylis

Norman Gaylis is a scholar working on Rheumatology, Hematology and Immunology, having authored 35 papers that have together received 1.2k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (22 papers), Systemic Lupus Erythematosus Research (12 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). The work is most often cited by research in Rheumatology (866 citations), Hematology (382 citations) and Genetics (219 citations). Norman Gaylis has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Jonathan Kay, Josef S Smolen, Elizabeth C. Hsia, Frederick T. Murphy, Eric L. Matteson, Mittie K. Doyle, Robert Landewé, Yiying Zhou, J. Wollenhaupt and Sudha Visvanathan. Their work appears in journals such as The Lancet, Clinical Infectious Diseases and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact